摘要
目的探讨益气养阴方联合卡瑞利珠单抗治疗气阴两虚型非小细胞肺癌(NSCLC)患者的临床效果。方法选取淄博市第四人民医院2021年6月—2024年6月收治的80例气阴两虚型NSCLC患者为研究对象,按随机数字表法将其分为对照组和观察组,各40例。对照组采用卡瑞利珠单抗治疗,观察组在对照组基础上加用益气养阴方治疗。比较两组的临床疗效、免疫功能、肿瘤标志物水平、中医证候积分及不良反应发生情况。结果观察组疾病控制率为90.00%,高于对照组的72.50%,差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)均高于对照组,CD8^(+)低于对照组,组间差异有统计学意义(P<0.05);观察组癌胚抗原、糖类抗原125、细胞角质蛋白19片段抗原21-1均低于对照组,组间差异有统计学意义(P<0.05);观察组咳嗽咳痰、气短气喘、口干舌燥、神疲体倦积分均低于对照组,组间差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论益气养阴方联合卡瑞利珠单抗治疗可降低气阴两虚型NSCLC患者的肿瘤标志物水平,增强疾病控制效果,且可增强免疫功能,安全可靠。
Objective To investigate the clinical effect of Yiqi Yangyin Decoction combined with camrelizumab in the treatment of patients with non-small cell lung cancer(NSCLC)with type of deficiency of both Qi and Yin.Methods A total of 80 patients with NSCLC type of deficiency of both Qi and Yin admitted to the Fourth People’s Hospital of Zibo from June 2021 to June 2024 were selected as the research objects,according to the random number table method,they were divided into a control group and an observation group,with 40 cases in each group.The control group was treated with camrelizumab,and the observation group was treated with Yiqi Yangyin Decoction on the basis of the control group.The clinical effect,immune function,tumor marker levels,Traditional Chinese Medicine syndrome scores and occurrence of adverse reactions were compared between the two groups.Results The disease control rate of the observation group was 90.00%,which was higher than 72.50%of the control group,and the difference was statistically significant(P<0.05).After treatment,CD3+and CD4+in the observation group were higher than those in the control group,and CD8+was lower than that in the control group,and the differences between the two groups were statistically significant(P<0.05);the carcinoembryonic antigen,carbohydrate antigen 125 and cytokeratin 19 fragment antigen 21-1 in the observation group were lower than those in the control group,and the differences between the two groups were statistically significant(P<0.05);the scores of cough and expectoration,shortness of breath,dry mouth,fatigue and body fatigue in the observation group were lower than those in the control group,and the differences between the two groups were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Yiqi Yangyin Decoction combined with camrelizumab treatment can reduce the levels of tumor markers in NSCLC patients with type of deficiency of both Qi and Yin,enhance the effect of disease control,and enhance the immune function,which is safe and reliable.
作者
田霞
TIAN Xia(Department of No.5 Oncology,The Fourth People’s Hospital of Zibo,Zibo 255000,China)
出处
《反射疗法与康复医学》
2025年第8期37-40,共4页
Reflexology And Rehabilitation Medicine
